<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377219</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/12/571</org_study_id>
    <secondary_id>PHRC 2012</secondary_id>
    <nct_id>NCT02377219</nct_id>
  </id_info>
  <brief_title>Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.</brief_title>
  <acronym>FIVPHENOL</acronym>
  <official_title>Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to prospect the relationships between Bisphenol A (BPA) exposure (measured as its
      free and conjugated forms in blood and urine) and embryo implantation rate (measured as the
      ratio between the number of gestational sacs and the number of transferred embryos) after
      assisted reproductive technology. In order to reduce the confusion factors, the population
      study is limited to young women (aged 28 to 34), with regular menstrual cycles and without
      any medical event that could affect the implantation process
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the various suspected adverse effects of BPA on human health, studies on the possible
      effects of BPA on reproduction are limited. Animal and in vitro studies indicate that BPA
      exposure can lead to disrupted oocyte maturation, E2 suppression and early pregnancy loss
      caused by chromosomal abnormalities. In the woman, studies about the consequences of BPA
      exposure on reproduction is a very difficult task since gametogenesis in the woman spreads
      over decades, from the intra-uterine life where meiosis is initiated to the end of the
      reproductive period at menopause. Recently, a decreased survival of human foetal oocytes
      cultured in vitro in the presence of BPA has been shown suggesting that in vivo exposure in
      foetal life could affect the ovarian reserve. Furthermore, a negative association between
      urinary BPA level and serum peak E2, oocyte yield and blastocyst formation has been suggested
      on a limited population of women performing ART. These results suggest that, in adulthood,
      both quantity and quality of human oocytes could be affected by BPA exposures. The study aims
      to respond to these questions by evaluating the relationships between BPA exposition levels
      and embryo implantation rates (as a marker of oocyte quality) and anti-Mullerian hormon (AMH)
      levels (as a marker of ovarian reserve) in large population of young adult women performing
      ART. BPA exposure will be assessed at two times in both blood and urine: 1°) before the
      ovarian stimulation at the time of ovarian reserve tests and 2°) at the end of the ovarian
      stimulation the day of the ovarian puncture for IVF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>embryo implantation rate</measure>
    <time_frame>6 weeks after implantation</time_frame>
    <description>an ultrasonography between the 5th and 7th week after embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum AMH</measure>
    <time_frame>4 days after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1388</enrollment>
  <condition>Female Reproductive Problem</condition>
  <condition>Male Reproductive Problems</condition>
  <arm_group>
    <arm_group_label>couples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hormonal and blood analysis</intervention_name>
    <arm_group_label>couples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Couples attending an IVF or ICSI attempt whose woman is aged 28 ans to 34 at inclusion
             time

          -  Regular menstrual cycles (between 27 and 33 days)

          -  1st or 2nd IVF or ICSI attempt with an embryo transfer at D2 or D3

        Exclusion Criteria:

          -  couple already included in the study

          -  ovarian surgery history

          -  uterine (malformation, diethylstilbestrol (DES) syndrome, adenomyosis…) or systemic
             pathology that can affect implantation (thrombophilia, antiphospholipids syndrome…)

          -  chemotherapy history for the woman

          -  any endocrinopathy (except dysthyroid) in the woman

          -  any pelvic surgery for the woman in the 3 months preceding inclusion

          -  endometriosis

          -  ICSI with testicular sperm

          -  Positive viral load for HIV, hepatitis C virus or hepatitis B virus (HCV or HBV)
             during the year preceding inclusion in one or both members of the couple
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger LEANDRI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger LEANDRI, MD</last_name>
    <phone>0033561778603</phone>
    <email>leandri.r@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHRU Brest Hôpital Morvan, Service de Médecine de la Reproduction</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia FAUQUE, MD</last_name>
      <phone>0033380295031</phone>
      <email>fauque.p@hu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia FAUQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine DECANTER, MD</last_name>
      <phone>0033320446897</phone>
      <email>christine.decanter@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Christine DECANTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges, Centre d'AMP</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>HOSPITAL</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne BERGER, MD</last_name>
      <phone>0033140258884</phone>
    </contact>
    <investigator>
      <last_name>Jacqueline SELVA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger LEANDRI, MD</last_name>
      <phone>00335617786003</phone>
      <email>leandri.r@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Roger LEANDRI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Corbel T, Gayrard V, Viguié C, Puel S, Lacroix MZ, Toutain PL, Picard-Hagen N. Bisphenol A disposition in the sheep maternal-placental-fetal unit: mechanisms determining fetal internal exposure. Biol Reprod. 2013 Jul 18;89(1):11. doi: 10.1095/biolreprod.112.106369. Print 2013 Jul.</citation>
    <PMID>23699389</PMID>
  </reference>
  <reference>
    <citation>Leandri RD, Gachet A, Pfeffer J, Celebi C, Rives N, Carre-Pigeon F, Kulski O, Mitchell V, Parinaud J. Is intracytoplasmic morphologically selected sperm injection (IMSI) beneficial in the first ART cycle? a multicentric randomized controlled trial. Andrology. 2013 Sep;1(5):692-7. doi: 10.1111/j.2047-2927.2013.00104.x. Epub 2013 Jun 21.</citation>
    <PMID>23788532</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisphenol A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

